Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aralez signs LOI to divest Canadian spec pharma operations to Nuvo; later signs definitive agreement

Executive Summary

Nuvo Pharmaceuticals Inc. signed a non-binding letter of intent (LOI) under a stalking-horse bid process to acquire Aralez Pharmaceuticals Inc.'s Canadian specialty pharmaceutical business, formerly known as Tribute Pharmaceuticals Canada Inc., along with associated personnel and infrastructure. Aralez plans to negotiate with Nuvo to execute a definitive agreement by August 19, 2018.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Intra-Biotech Deal
    • Includes Contract
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register